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Abstract
OBJECTIVE—In October 2011, the Advisory Committee on Immunization Practices (ACIP) 
recommended the quadrivalent human papillomavirus vaccine (HPV4) for the routine 
immunization schedule for 11- to 12-year-old boys. Before October 2011, HPV4 was permissively 
recommended for boys. We conducted a study in 2010 to provide data that could guide efforts to 
implement routine HPV4 immunization in boys. Our objectives were to describe primary care 
physicians’: 1) knowledge and attitudes about human papillomavirus (HPV)-related disease and 
HPV4, 2) recommendation and administration practices regarding HPV vaccine in boys compared 
to girls, 3) perceived barriers to HPV4 administration in boys, and 4) personal and practice 
characteristics associated with recommending HPV4 to boys.
METHODS—We conducted a mail and Internet survey in a nationally representative sample of 
pediatricians and family medicine physicians from July 2010 to September 2010.
RESULTS—The response rate was 72% (609 of 842). Most physicians thought that the routine 
use of HPV4 in boys was justified. Although it was permissively recommended, 33% 
recommended HPV4 to 11- to 12-year-old boys and recommended it more strongly to older male 
adolescents. The most common barriers to HPV4 administration were related to vaccine financing. 
Physicians who reported recommending HPV4 for 11- to 12-year-old boys were more likely to be 
from urban locations, perceive that HPV4 is efficacious, perceive that HPV-related disease is 
severe, and routinely discuss sexual health with 11- to 12-year-olds.
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CONCLUSIONS—Although most physicians support HPV4 for boys, physician education and 
evidence-based tools are needed to improve implementation of a vaccination program for males in 
primary care settings.
Keywords
HPV vaccine; immunization; physician attitudes
The quadrivalent human papillomavirus vaccine (HPV4) protects vaccinated individuals 
from the cancer-causing human papillomavirus (HPV) strains, 16 and 18, and the wart-
causing strains, 6 and 11. Until October 2011, HPV4 was recommended only for females; 
however, approximately 7000 HPV-associated cancers and 250,000 cases of genital warts 
occur in males in the United States annually, with the highest risk for immuno-compromised 
men, and men who have sex with men.1–8 Vaccination of men reduces disease caused by 
these HPV types in men and also reduces transmission of HPV to females.3 In 2009, the US 
Food and Drug Administration licensed HPV4 for use in males aged 9 through 26 years for 
prevention of genital warts.9 Soon after licensure, the Advisory Committee on Immunization 
Practices (ACIP) provided guidance that HPV4 may be used in males aged 9 to 26 years but 
did not recommend HPV4 for routine use.10 The vaccine was included in the Vaccines for 
Children program to enable providers to immunize eligible boys aged 9 through 19. In 
October 2011, the ACIP modified its guidance and recommended HPV4 for routine use in 
boys.
Before our study, conducted in 2010 when HPV4 was permissively recommended for boys, 
limited data were available regarding primary care physicians’ knowledge, attitudes, and 
practices related to HPV4 for males. These data were needed to aid the ACIP in its 
consideration of the acceptability of an HPV vaccination program for males among primary 
care providers and to guide implementation efforts if a recommendation for routine use were 
made.11–15 Because HPV vaccine coverage among girls remained below 50% three years 
after it was recommended and coverage improved less than for other adolescent vaccines,16 
challenges to implementation were expected for boys. Information about the characteristics 
of physicians who were recommending HPV4 for boys and the circumstances under which 
they recommended it when it was permissively recommended by the ACIP could identify 
interventions to increase physicians’ use of HPV4. Therefore, we conducted a survey among 
a nationally representative sample of pediatricians and family medicine (FM) physicians to: 
1) describe their knowledge and attitudes about HPV-related disease and HPV4 for males, 2) 
describe their recommendation and administration practices regarding HPV vaccine in boys 
compared to girls, 3) describe perceived barriers to HPV4 administration in boys, and 4) 
identify physician and practice characteristics associated with recommending HPV4 to boys.
Methods
Study Setting
The Vaccine Policy Collaborative Initiative, a program designed collaboratively with the 
Centers for Disease Control and Prevention (CDC) to assess primary care physicians’ 
attitudes about vaccine-related issues, administered a survey to a national network of 
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pediatricians and FM physicians. The human subjects review board at the University of 
Colorado approved this study as exempt research.
Population
We conducted the survey among networks of physicians who were previously recruited from 
the American Academy of Pediatrics (AAP) and American Academy of Family Physicians 
(AAFP) and who agreed to respond to several surveys annually.17 After obtaining twice the 
number of recruits needed for each network, a quota strategy was applied to assure the 
representativeness of the samples.17,18 In a previous evaluation, demographic characteristics, 
practice attributes, and reported attitudes about a range of vaccination issues were generally 
similar when network physicians were compared with physicians of the same specialty 
randomly sampled from the American Medical Association master physician listing.17
Survey Design
We developed the survey instrument in collaboration with the CDC. On the basis of the 
Health Belief Model, we predicted that physicians’ recommendation for HPV4 in boys is 
affected by their perceptions about barriers to HPV4 administration, males’ susceptibility to 
HPV infection and HPV-related diseases, severity of HPV-related diseases, and the benefit of 
HPV4.19 Because previous studies of the HPV vaccine have indicated that some physicians 
link counseling about the vaccine to counseling about sexual health,14,20,21 we also asked 
about physicians’ practices related to discussing sexual health with boys and girls at 
different ages. We predicted that discussing sexual health issues would be a cue to action for 
recommending HPV4.
The survey also included questions about physicians’ and practices’ characteristics, 
physicians’ current practices related to recommendation for and administration of the HPV 
vaccine, physicians’ knowledge about HPV infection and HPV4 among males, the topics 
physicians would emphasize when discussing HPV4 with male patients, and physicians’ 
intention to recommend HPV4 for boys if recommended for routine use by the ACIP. The 
survey was pretested in a community advisory panel consisting of 3 pediatricians and 3 FM 
physicians from across the country and was pilot tested among 41 pediatricians and FM 
physicians.
We measured physicians’ perceived barriers to HPV4 administration to boys, perceptions of 
HPV4 and HPV-related diseases, current practices regarding recommendation of the HPV 
vaccine, topics of emphasis when discussing HPV4 with boys, and intention to recommend 
HPV4 for boys if recommended for routine use by the ACIP using 4-point Likert scales. We 
measured physicians’ current administration practices using 5 choices ranging from “never/
almost never” to “always/almost always.” We measured physicians’ knowledge about the 
HPV vaccine and HPV-related diseases and perception of HPV4 efficacy in males using 
statements to which respondents answered “agree,” “disagree,” or “don’t know/not sure.” 
Finally, we measured physicians’ discussion of sexual health at different ages using “yes” or 
“no” choices.
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Survey Administration
The survey was administered between July 2010 and September 2010 by Internet or regular 
mail based on physicians’ preferences. The Internet survey was administered using a Web-
based program (Vovici Corp, Dulles, Va). The Internet group received an initial e-mail with 
a link to the survey and up to 8 e-mail reminders to complete the survey, while the mail 
group received an initial mailing and up to 2 additional mailed surveys at 2-week intervals. 
The Internet nonresponders also received up to 2 paper surveys by mail.
Analytic Methods
Internet and mail surveys were pooled for all analyses, as provider attitudes have been found 
to be comparable when obtained by either method.22 We compared pediatricians and FM 
physicians by chi-square tests for questions with dichotomous responses and Kolmogorov-
Smirnov tests for questions with Likert scale responses. Because pediatricians’ and FM 
physicians’ responses were similar, they were combined for most subsequent analyses. The 
Cochran-Armitage test for trend was used to compare the strength of recommendation for 
HPV across different age groups and the frequency of discussing sexual health issues across 
different age groups.
Perceived barriers to HPV4 administration in boys were grouped into 4 categories: vaccine 
financing issues (4 questions), parental attitudes about HPV4 for boys (5 questions), logistic 
barriers to HPV administration (4 questions), and physicians’ attitudes about the safety of 
HPV4 and its effect on boys’ behavior (4 questions). Susceptibility was measured with 3 
questions, and severity was measured with 3 questions. A Cronbach alpha value was 
calculated for each set of questions measuring a specific concept (barriers, susceptibility, and 
severity) to determine whether physicians responded in a consistent manner. Because the 
Cronbach alpha value was greater than 0.70 for each concept, we created scales for the 4 
barrier concepts, susceptibility, and severity by assigning a number value from 0 to 4 for 
each response, adding the numbers, and dividing by the number of questions in the set.
We compared physicians who reported recommending HPV4 to their 11- to 12-year-old 
male patients (recommend strongly or recommend, but not strongly) to physicians who 
reported making no recommendation or recommending against HPV4 in terms of physician 
characteristics (age, gender, and specialty), practice characteristics (region of country, urban 
vs rural, proportion of patients 11 to 18 years old, and proportion of patients with private 
insurance), perceived barriers, susceptibility, severity, benefit, and cue to action by using t 
tests, Wilcoxon tests, and chi-square tests, as appropriate. Predictor variables with a P value 
of .25 or less were included in a multivariable logistic regression model. Variables were 
retained in the final model if their P values were <.05.
Results
Response Rates and Sample Characteristics
Our response rate was 72% overall, with 82% of pediatricians (343 of 419) and 63% of FM 
physicians (266 of 423) responding. The response rate was 76% for the Internet survey 
group (404 of 533) and 66% for the mailed survey group (205 of 309). Respondents were 
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similar to nonrespondents (Table 1). However, respondents were more likely to be women, 
more recent medical school graduates, and more likely to practice in an academic, 
community health center, or public health setting compared to nonrespondents.
Knowledge and Attitudes About HPV-related Disease and HPV4 for Males
Although most physicians agreed that most male subjects with HPV infection are 
asymptomatic, 25% disagreed or were unsure. Although the majority agreed that genital 
warts and cervical cancers are caused by different HPV types, 48% disagreed or were 
unsure. Most physicians (85%) agreed that HPV infection causes some penile, anal, and oral 
cancers in male subjects, and 64% agreed that the incidence of HPV-associated anal cancer 
is higher among men who have sex with men. Seventy-four percent agreed that HPV4 is 
efficacious for preventing genital warts in male subjects.
More physicians strongly agreed that “since HPV is transmitted from males to females, 
HPV-related disease is severe enough in females to justify routine use of HPV4 in males” 
than strongly agreed that “HPV-related disease is severe enough in males to justify the 
routine use of HPV4 in males” (Fig. 1). Fifty-four percent of physicians strongly or 
somewhat agreed that it is necessary to discuss issues of sexuality before recommending 
HPV4 to their male patients. When discussing HPV4, 65% would strongly emphasize 
prevention of genital warts in the patient himself, 64% would strongly emphasize prevention 
of cervical cancer in the patient’s female partners, and 60% and 56% would strongly 
emphasize vaccine safety and efficacy, respectively.
Practices Related to HPV4 in Girls and Boys
The majority of physicians reported that they routinely recommend the HPV vaccine for 
girls, while a minority reported that they routinely recommend HPV4 for boys (Fig. 2). For 
both genders and subspecialties, physicians were more likely to strongly recommend the 
vaccine for adolescents aged 13 to 15 and 16 to 18 compared to 11-to 12-year-olds (P < .
0001 for girls, P = .01 for boys). Ninety-two percent of physicians reported that they 
administer the HPV vaccine to girls in their practices, and 31% reported that they administer 
the vaccine to boys.
When asked about the strength of their recommendation if the ACIP were to recommend 
HPV4 for routine use among boys, only 37% of physicians reported that they intended to 
strongly recommend HPV4 for 11- to 12-year-old boys, 42% intended to recommend but not 
strongly, 17% intended to make no recommendation, and 3% intended to recommend 
against. Eighty-four percent of physicians reported they would strongly recommend HPV4 
for boys who have disclosed that they are homosexual or bisexual.
When physicians were asked whether they routinely discuss sexual activity at health 
maintenance visits for each gender by age group, 31% reported that they discuss this topic 
with 11- and 12-year-old girls and 27% discuss with 11- and 12-year-old boys. More than 
80% reported discussing sexual activity with 13- to 15-year-olds and 16- to 18-year-olds. 
For a similar question about discussion of sexual orientation, 11% of physicians routinely 
discuss this topic with both 11- to 12-year-old boys and girls, 37% discuss with both 13- to 
15-year-old boys and girls, and 52% discuss with both 16- to 18-year-old boys and girls. 
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Pediatricians’ and FM physicians’ practices regarding discussion of sexual health were not 
statistically different.
Barriers to HPV4 Administration in Boys
The most commonly reported barriers to HPV4 administration if recommended for routine 
use in boys were related to vaccine financing, with 89% of physicians reporting at least one 
barrier in this category (Table 2). Barriers related to physicians’ perceptions of parental 
attitudes about HPV4 for boys and the logistics of HPV4 administration were also 
commonly reported. The most common parental attitude barrier was “parents not thinking 
that HPV4 is necessary for their sons” and the most common logistic barrier was “infrequent 
office visits made by male adolescent patients.” Barriers related to physicians’ attitudes 
about the safety of HPV4 and the effect of HPV4 vaccination on boys’ behavior were 
uncommon.
Characteristics Associated With Recommending HPV4 to 11- to 12-Year-Old Boys
On the basis of the bivariate analysis, the following variables were included in the 
multivariable analysis to determine characteristics associated with recommending HPV4 for 
11- to 12-year-old boys: region of the country, urban versus rural location, proportion of 
patients aged 11 to 18 years, proportion of patients with private insurance, physicians’ 
gender, the 4 barrier scales, the susceptibility scale, the severity scale, physicians’ perception 
of HPV4 efficacy, and whether physicians routinely discussed sexual activity with 11- to 12-
year-old boys (Table 3). Physicians were less likely to recommend HPV4 for their 11- to 12-
year-old male patients if they practiced in a rural location and disagreed or didn’t know that 
HPV4 is efficacious for preventing genital warts in males. Physicians were more likely to 
recommend HPV4 if they routinely discuss sexual activity with 11- to 12-year-old boys and 
had higher scores on the scale measuring their perception of HPV severity.
Discussion
In a national survey conducted when HPV4 was permissively recommended for boys, we 
found that the majority of pediatricians and FM physicians thought that routine use of HPV4 
in boys was justified to protect both boys and their future female partners; however, few 
physicians reported recommending or administering HPV4 to boys. Physicians who reported 
recommending HPV4 for 11- to 12-year-old boys were more likely to be from urban 
locations, perceive that HPV4 is efficacious, perceive that HPV-related disease is severe, and 
routinely discuss sexual health issues with 11- to 12-year-olds. Although the majority of 
physicians report that they would strongly recommend HPV4 for the subset of adolescent 
male subjects who are likely to have same-sex sexual encounters, they do not regularly ask 
about sexual orientation, making this sort of targeted vaccination strategy very unlikely to 
occur in practice.
In October 2011, on the basis of evidence of vaccine efficacy and safety, cost-effectiveness 
estimates (in the context of HPV vaccine coverage at 50% or less in girls16), and 
programmatic considerations, the ACIP changed its permissive recommendation to a 
stronger recommendation to include HPV4 in the routine immunization schedule for 11- to 
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12-year-old boys with catch-up vaccination of males aged 13 through 21 years.3 HPV4 was 
recommended at age 11 to 12 because it is most effective if provided before initiation of 
sexual activity and exposure to HPV,23,24 the antibody response to vaccine is better at this 
age compared to older adolescents,3 and because 2 additional vaccines, the meningococcal 
conjugate vaccine (MCV) [this abbreviation is used later] and the tetanus, diphtheria, and 
acellular pertussis vaccine, are also recommended at this age.25 This recommendation is 
consistent with the current recommendation for girls.25
Our findings are similar to studies about health care providers’ willingness to recommend 
HPV4 to boys that were mainly conducted before the ACIP’s permissive recommendation.
11–15,26,27
 Despite the ACIP’s recommendation to administer HPV4 to boys at 11 to 12, 
physicians were more likely to strongly recommend it as their adolescent male patients’ age 
increased. HPV vaccine may have a role in promoting communication between providers, 
parents, and patients about sexual health issues28,29; however, a minority of physicians 
reported routinely discussing these issues with 11- to 12-year-olds for whom the HPV 
vaccine is recommended. Our finding that physicians who routinely discuss sexual health 
issues at 11 to 12 years were more likely to report recommending HPV4 to 11- to 12-year-
old boys supports the idea that physicians are linking discussion of sexual health with a 
recommendation for the HPV vaccine. Physicians could discuss the HPV vaccine solely 
focusing on cancer prevention or bundled in a discussion of the other recommended 
adolescent vaccines. However, HPV4 for boys may be unique because physicians’ belief that 
prevention of cervical cancer in female partners is as important as preventing cancer in the 
male patient himself may make them think that they must discuss sex. Because early 
adolescents may look to their parents for guidance on preventive health care issues, 
discussions about the implications of HPV may be occurring more with parents of younger 
adolescents than with the adolescents themselves.30–32 Therefore, the perspectives of the 
parents are important.
Studies show that a health care provider’s recommendation is critical when adolescents and 
their parents are deciding whether to receive the HPV vaccine.26,33–35 We found that only 
14% of physicians reported strongly recommending HPV4 to 11- to 12-year-old boys when 
it was permissively recommended by ACIP, and only 37% reported that they intended to 
strongly recommend HPV4 for 11- to 12-year-olds if the ACIP recommended HPV4 for 
routine immunization of boys. Although physicians’ reported strength of recommendation is 
a subjective measure, our data suggest that physicians may not be endorsing HPV4 for boys 
as strongly as they are for girls or for other recommended adolescent vaccines. National 
estimates suggest that 8.3% of adolescent boys received at least 1 dose of HPV4 in 2011.36 
Data from 2012 will reveal whether the ACIP’s change from a permissive to a routine 
recommendation significantly increases boys’ receipt of HPV4.
Our study results suggest some interventions focused on primary care providers to increase 
HPV4 vaccination of boys. First, given that physicians are linking discussion of sexual 
health issues with recommending HPV4, primary care providers could benefit from 
evidence-based tools to help them communicate with parents and patients at different 
developmental stages about sexual health, including HPV vaccine. Second, because we 
found that physicians who perceived HPV-related disease to be severe and HPV4 to be 
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efficacious were more likely to recommend HPV4, public health officials can continue to 
disseminate data about the severity of HPV-related diseases and the efficacy of HPV4 in 
preventing these diseases. At the time of our survey, data were strongest about the efficacy 
of HPV4 for prevention of genital warts in males. Since then, additional data have been 
published about the efficacy of HPV4 for prevention of anal cancer37 and the increasing 
incidence of HPV-related oropharyngeal and esophageal cancers.38 Dissemination of this 
information may increase physicians’ perception of the importance of HPV4. Finally, 
because more physicians strongly recommended HPV4 at ages 16 to 18, public health 
officials could consider promoting catch-up vaccination of 16 year olds. A booster dose of 
MCV is now recommended at age 16 so these adolescents could be targeted for both MCV 
and HPV4.39
The perceived barriers to HPV4 administration for boys identified in this study are similar to 
barriers identified by other studies of adolescent vaccines.20,40–45 In all of these studies, 
vaccine financing issues were important barriers. The Affordable Care Act’s requirement 
that all nongrandfathered insurance plans must cover childhood vaccines is expected to 
alleviate some, but not all, of the financial barriers experienced by primary care providers. A 
commonly reported programmatic barrier is lack of office visits by adolescent patients. 
Because older adolescent boys are less likely to have an office visit than younger adolescent 
boys,46–48 catch-up vaccination of older boys could be particularly challenging. Finally, 
although only 11% of physicians reported concern about the safety of HPV4, this minority 
may undermine the perception of vaccine safety among many families.49
This study has important strengths and limitations. The surveyed physicians were shown in 
previous studies to be generally representative of physicians in the AAP and AAFP with 
respect to demographic and practice characteristics and locations throughout the United 
States.17 Although the response rate was high, the response was lower from FM physicians 
than pediatricians. Although the sample seemed representative, those who agreed to be 
surveyed might not have expressed similar views as those who chose not to be in the 
network and those who did not respond to the survey. Finally, physicians’ practices 
regarding HPV4 may have changed now that HPV4 is recommended for routine use in boys; 
however, it is unlikely that barriers to vaccine delivery, physicians’ knowledge and attitudes 
about HPV4, and physicians’ practices related to discussing sexual health have changed 
significantly without further intervention.
Conclusion
Continued evaluation will determine whether the recent recommendation to include HPV4 in 
the routine immunization schedule for boys will result in improved vaccine coverage. 
Primary care providers need support to implement effective systems, such as reminder-
recall,50,51 to improve delivery of HPV and other adolescent vaccines at the 11- to 12-year-
old preventive visit and at catch-up visits for older adolescents. In addition to the HPV 
vaccine, our findings could provide guidance for implementation of future adolescent 
vaccine recommendations. If other vaccines to prevent sexually transmitted infections are 
developed and recommended for adolescents, primary care physicians would benefit from 
clear, evidence-based guidance about how to discuss these vaccines with parents and with 
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adolescents at different developmental stages. Our study suggests that when new adolescent 
vaccines become available, higher vaccine coverage—and ultimately prevention of disease
—are more likely to be achieved if physicians are convinced that the diseases are severe and 
vaccines are efficacious, financial barriers are removed, and novel ways of reaching 
adolescents are utilized.
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WHAT’S NEW
Our survey findings suggest that primary care-focused interventions to improve human 
papillomavirus (HPV) vaccination of boys should include tools to help providers 
communicate with parents and patients about HPV vaccine and sexual health, 
dissemination of data about HPV-related disease severity and vaccine efficacy, and 
promotion of catch-up vaccination at age 16.
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Figure 1. 
Physicians’ attitudes about HPV4 for boys for pediatricians and family physicians combined 
(n =602). Excluded are physicians who responded, “I do not see patients in this group” (total 
excluded <2%). Some percentages do not add up to 100% because of rounding.
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Figure 2. 
Physicians’ strength of recommendation for HPV vaccine in girls and boys in different age 
groups (n = 609). The survey was conducted between July 2010 and September 2010 before 
the recommendation for routine vaccination of boys with HPV4. Excluded physicians who 
responded, “I do not see patients in this age group” (total excluded <2%). Some percentages 
do not add up to 100% because of rounding. P < .05 for Cochran-Armitage test for trend for 
percent who “strongly recommend” and “recommend, but not strongly” across the 3 age 
groups for both genders.
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Table 1
Comparison of Respondents and Nonrespondents and Additional Characteristics of Respondents’ Practices
Family Medicine Pediatricians
Characteristic
Nonrespondents (n = 
157, 37%)
Respondents (n = 
266, 63%)
Nonrespondents (n = 
76, 18%)
Respondents (n = 
343, 82%)
Year of MD/DO school graduation, 
median
1987 1986 1983.5 1988*
Female, % 25 46* 49 63*
Region of country, %
 Midwest 32 28 22 20
 Northeast 15 16 21 23
 South 31 34 38 35
 West 22 22 18 23
Practice location, %
 Rural 23 27 15 12
 Urban, inner city 29 28 35 45
 Urban, non–inner city/suburban 48 45 51 43
Type of practice, %
 Health maintenance organization 6 2 0 5
 Private practice 77 75 82 78
 Community or hospital based 17 23* 18 17
Proportion of 11- to 18-year-old patients
 <10% 51 3
 10–29% 41 28
 30–39% 4 33
 ≥40% 4 35
Proportion of uninsured patients
 <10% 71 85
 10–24% 20 13
 ≥25% 9 3
Proportion of patients with Medicaid or SCHIP, %
 <10% 44 28
 10–24% 23 25
 25–49% 19 23
 ≥50% 14 24
Proportion of patients with private insurance, %
 <25% 22 18
 25–49% 22 18
 50–74% 29 29
 ≥75% 27 35
Proportion of Latino patients, %
 <10% 70 53
 10–24% 15 28
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Family Medicine Pediatricians
Characteristic
Nonrespondents (n = 
157, 37%)
Respondents (n = 
266, 63%)
Nonrespondents (n = 
76, 18%)
Respondents (n = 
343, 82%)
 ≥25% 15 19
Proportion of black/African American patients, %
 <10% 67 49
 10–24% 22 30
 >25% 11 20
SCHIP = State Children’s Health Insurance Program.
*P < .05 for comparison between respondents and nonrespondents within specialty.
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Table 2
Perceived Barriers to HPV4 Administration if Recommended for Routine Use in Boys, Pediatricians and 
Family Medicine Physicians Combined (N = 593)*
Barrier Major Barrier, %
Somewhat a 
Barrier, % Minor Barrier, %
Not a 
Barrier, %
Vaccine financing issues
 Failure of some insurance companies to cover HPV4 for boys 56 27 8 8
 Lack of adequate reimbursement for vaccination 49 27 12 11
 Parents unable to pay the out-of-pocket cost for vaccine 48 28 13 11
 The up-front costs for my practice to purchase the vaccine 24 27 23 26
Parental attitudes about HPV4 for boys
 Parents not thinking that HPV4 is necessary for their sons 19 45 29 7
 Parents’ opposition to HPV4 vaccination for moral or 
religious reasons
13 26 46 15
 Parents’ concern about the safety of HPV4 for their sons 11 33 43 13
 Parents’ concern that vaccination may encourage earlier 
sexual behavior
6 25 41 28
 Parents’ concern that vaccination may encourage riskier 
sexual behavior
5 25 42 28
Logistic barriers to HPV4 administration
 Infrequent office visits made by male adolescent patients 12 38 34 17
 Difficulty ensuring completion of 3-dose vaccine series 11 35 41 13
 The time it will take me to discuss HPV4 7 19 41 34
 General administrative a burden to my practice 7 18 32 43
Providers’ attitudes about the safety of HPV4 and effect of 
HPV4 vaccination on boys’ behavior
 My concern about the safety of HPV4 for boys 4 7 21 69
 My concern that vaccination may encourage riskier sexual 
behavior
1 5 13 82
 My concern that vaccination may encourage earlier sexual 
behavior
1 4 11 85
 My opposition to HPV4 vaccination for moral or religious 
reasons
1 1 3 95
HPV = human papillomavirus; HPV4 = quadrivalent HPV vaccine.
*Some % do not add up to 100% because of rounding.
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Table 3
Practice and Physician Characteristics Associated With Recommending the HPV4 Vaccine to 11- to 12-Year-
Old Boys
Characteristic Unadjusted OR (95% CI) Adjusted OR (95% 
CI)
Physician gender
 Female 1.28 (0.90–1.82)
 Male Reference
Region of country
 Midwest 0.74 (0.46–1.17)
 Northeast 0.52 (0.31–0.88)
 West 0.89 (0.56–1.41)
 South Reference
Practice location
 Rural 0.53 (0.33–0.87) 0.50 (0.30–0.85)
 Urban Reference Reference
Percentage of healthy children aged 11–18 in practice
 0–9% 0.67 (0.42–1.06)
 10–29% 1.01 (0.68–1.49)
 ≥30% Reference
Percentage of patients with private insurance in practice
 0–24% 1.45 (0.87–2.39)
 25–74% 1.20 (0.80–1.81)
 ≥75% Reference
Agree that HPV4 is efficacious for preventing genital warts in boys (physicians’ 
perception of benefit)
 No or don’t know 0.48 (0.31–0.74) 0.57 (0.36–0.91)
 Yes Reference Reference
Routinely discuss sexual activity with male patients 11–12 years old (cue to action)
 Yes 2.27 (1.55–3.32) 2.24 (1.49–3.38)
 No Reference Reference
Physicians’ perception of boys’ susceptibility to HPV scale (per increasing point) 2.86 (2.03–4.02)
Physicians’ perception of HPV severity scale (per increasing point) 3.56 (2.46–5.16) 3.29 (2.25–4.81)
Barriers
 Vaccine financing issues scale (per increasing point) 0.93 (0.75–1.14)
 Parental attitudes about HPV4 scale (per increasing point) 0.80 (0.61–1.04)
 Logistic barriers to HPV4 administration scale (per increasing point) 0.75 (0.57–0.97)
 Provider attitudes about the safety of HPV4 scale (per increasing point) 0.62 (0.38–0.99)
HPV = human papillomavirus; HPV4 = quadrivalent HPV vaccine; OR = odds ratio; CI = confidence interval.
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